/
RSS Feed
Tamoxifen After Chemotherapy Protects Premenopausal Patients with Breast Cancer
ABSTRACT: J Clin Oncol 24:1322, 2006
Gordon McVie, European Institute of Oncology, Milan
The use of tamoxifen after chemotherapy for premenopausal patients with breast cancer has been shown to almost double disease-free survival among estrogen receptor positive patients, with the greatest benefits among younger patients. These findings emerge from a publication in the Journal of Clinical Oncology by the International Breast Cancer Study group, led by Marco Colleoni of Milan. Gordon McVie from the European Institute of Oncology comments.
Gordon McVie, European Institute of Oncology, Milan
The use of tamoxifen after chemotherapy for premenopausal patients with breast cancer has been shown to almost double disease-free survival among estrogen receptor positive patients, with the greatest benefits among younger patients. These findings emerge from a publication in the Journal of Clinical Oncology by the International Breast Cancer Study group, led by Marco Colleoni of Milan. Gordon McVie from the European Institute of Oncology comments.
Gene Expression Blood Test for Earlier Breast Cancer Detection?
REFERENCE: 2006 American Association for Cancer Research Annual Meeting, April 1-5, Washington, DC, Abstract 125
Anne-Lise Børresen-Dale, Norwegian Radium Hospital, Oslo
A Norwegian group has identified genes that discriminate breast cancer from non-breast cancer tissues and used them in a blood test for breast cancer and reported high specificity and sensitivity at the 2006 American Association for Cancer Research Annual Meeting in Washington, DC. Anne-Lise Børresen-Dale discussed her results with Karen Regester.
Anne-Lise Børresen-Dale, Norwegian Radium Hospital, Oslo
A Norwegian group has identified genes that discriminate breast cancer from non-breast cancer tissues and used them in a blood test for breast cancer and reported high specificity and sensitivity at the 2006 American Association for Cancer Research Annual Meeting in Washington, DC. Anne-Lise Børresen-Dale discussed her results with Karen Regester.
Blood Test of Gene Methylation Detects Early Colorectal Cancer
REFERENCE: 2006 American Association for Cancer Research Annual Meeting, April1-5, Washington, DC, Abstract LB-224
Catherine E. Lofton-Day, Epigenomics Inc., Seattle
A new blood test for colorectal cancer that looks for methylation of the septin 9 gene has been found to be more sensitive and specific than fecal occult blood when tested on samples from colonoscopy-defined individuals with colorectal cancer, as compared to those without the disease. Catherine Lofton-Day from Epigenomics Inc. of Seattle talked about the test during the 2006 American Association for Cancer Research Annual Meeting in Washington, DC.
Catherine E. Lofton-Day, Epigenomics Inc., Seattle
A new blood test for colorectal cancer that looks for methylation of the septin 9 gene has been found to be more sensitive and specific than fecal occult blood when tested on samples from colonoscopy-defined individuals with colorectal cancer, as compared to those without the disease. Catherine Lofton-Day from Epigenomics Inc. of Seattle talked about the test during the 2006 American Association for Cancer Research Annual Meeting in Washington, DC.
Airway Gene Signatures Detect Early Lung Cancer
REFERENCE: 2006 American Association for Cancer Research Annual Meeting, April1-5, Washington, DC, Abstract 2420
Avrum Spira, Boston University
Airway gene signatures may be the ideal test to be added to bronchoscopy for diagnosing early lung cancer according to findings presented to the 2006 American Association for Cancer Research Annual Meeting in Washington, DC. Avrum Spira from Boston University said that where bronchoscopy is weakest, gene profiling is strongest: picking up 90 % of early cancers, as compared with only 30 % from bronchoscopy alone.
Avrum Spira, Boston University
Airway gene signatures may be the ideal test to be added to bronchoscopy for diagnosing early lung cancer according to findings presented to the 2006 American Association for Cancer Research Annual Meeting in Washington, DC. Avrum Spira from Boston University said that where bronchoscopy is weakest, gene profiling is strongest: picking up 90 % of early cancers, as compared with only 30 % from bronchoscopy alone.
Nicotine Can Inhibit Lung Cancer Chemotherapy
REFERENCE: 2006 American Association for Cancer Research Annual Meeting,April 1-5, 2006, Washington, DC, Abstract 787
Piyali Dasgupta, H. Lee Moffitt Cancer Center, Tampa
Smoking has been observed to reduce the effectiveness of chemotherapy for non-small cell lung cancer, and according to findings presented to the 2006 American Association for Cancer Research Annual Meeting in Washington, DC, it is the nicotine in cigarette smoke that is mainly responsible for the effect, and not necessarily the hundreds of other toxic components of the smoke. Pivali Dasgupta from the Moffitt Cancer Center in Tampa told Audio Medica about her findings.
Piyali Dasgupta, H. Lee Moffitt Cancer Center, Tampa
Smoking has been observed to reduce the effectiveness of chemotherapy for non-small cell lung cancer, and according to findings presented to the 2006 American Association for Cancer Research Annual Meeting in Washington, DC, it is the nicotine in cigarette smoke that is mainly responsible for the effect, and not necessarily the hundreds of other toxic components of the smoke. Pivali Dasgupta from the Moffitt Cancer Center in Tampa told Audio Medica about her findings.
Intraperitoneal Therapy and Survival in Ovarian Cancer
ABSTRACT:J Clin Oncol 24:1322, 2006, N Engl J Med 354:3, 2006
Gordon McVie, European Institute of Oncology, Milan
Intraperitoneal therapy for ovarian cancer has achieved successes recently with improvements in median survival among patients receiving a number of different regimens intraperitoneally as compared with intravenously, and a new study from Nijmegen on the use of monoclonal antibody known to target cells has now been published in the Journal of Clinical Oncology. Gordon McVie from the European Institute of Oncology comments on these reports, and about the potential for improving ovarian cancer survival based on the new therapies recently investigated.
Gordon McVie, European Institute of Oncology, Milan
Intraperitoneal therapy for ovarian cancer has achieved successes recently with improvements in median survival among patients receiving a number of different regimens intraperitoneally as compared with intravenously, and a new study from Nijmegen on the use of monoclonal antibody known to target cells has now been published in the Journal of Clinical Oncology. Gordon McVie from the European Institute of Oncology comments on these reports, and about the potential for improving ovarian cancer survival based on the new therapies recently investigated.
[audio:https://www.audiomedica.com/podcasting/asco/06.05.01_AJONC_podcast.mp3]
